Certara Q3 revenue up 1% to $85.6M; net loss $49.0M on $47M goodwill impairment

Certara, Inc.

2023-Q3 EPS reported -$0.27 revenue$266,327,000

Revenue $85.6M (+1% YoY); regulatory revenue declined but biosimulation demand stable.
Net loss $49.0M vs net income $3.9M in Q3 2022; includes $47.0M goodwill impairment in Regulatory business.
Adjusted EBITDA $28.8M vs $32.7M YoY; adjusted net income $17.1M vs $16.6M YoY.
Reiterates full year 2023 guidance; bookings recovery in services and strong software pipeline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Certara, Inc. updated its third quarter of fiscal year 2023 guidance (reaffirmed).

Period: third quarter of fiscal year 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On November 8, 2023 , Certara, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Certara, Inc. filing history →

Source: SEC EDGAR

accession 0001827090-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.